Welcome to CAB at St. Jude

The CAB Genetics Group focuses on the association of inherited or acquired genetic variations with clinical or phenotypic traits in humans. We are also interested in establishing new bioinformatic and statistical pipelines to enhance researching practices of St. Jude investigators.

We mainly focus on these areas:

  • Germline pediatric cancer
  • Pediatric neurogenetics
  • Annotations and interpretation of non-coding variants

We categorized Genetics Analyses briefly into three major topics:

  • Individual studies: ACMG/AMP 2015 classification of germline variants.
  • Family studies: Segregation and filtering approaches for novel variant discovery.
  • Cohort studies: Testing and application of published methods for single variant, gene-based, and pathway-level analyses of large cohorts.

Technologies and methods

The CAB Genetics Group is primarily a statistical genetics/bioinformatic group that uses a wide range of genomic, bioinformatic, and statistical methods including:

  • Amplicon sequencing
  • WES
  • WGS
  • RNA-Seq

Joining St. Jude

If you are interested in joining please go to the recruitment page.


July 1th 2022

New papers! Dickerson et al. 2022; BloodCancerDiscovery;Zhao et al. 2022; JNCI;Drosos et al. 2022; MolecularCell;Graca et al. 2022; NatCommun; Kudo to Wojciech, co-first author Qi et al. 2022; JPathol;

Oct 19th 2021

New paper! Wang et al. 2021 published in Life Sci. Alliance: PROSER1 mediates TET2 O-GlcNAcylation to regulate DNA demethylation on UTX-dependent enhancers and CpG islands. Kudo to Wojciech, first co-first author with St. Jude PIs

Aug 24th 2021

New paper! Xu et al. 2021 published in Genome Bio.: Acute depletion of CTCF rewires genome-wide chromatin accessibility. Press Release

Jun 8th 2021

New paper! Montefiori et al. 2021 published in Cancer Discov.: Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage Ambiguous Stem Cell Leukemia

Jun 4th 2021

New paper! Zong et al. 2021 published in J. Exp. Med.: Foxp3 Enhancers Synergize to Maximize Regulatory T Cell Suppressive Capacity

... see all News